Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
Integra LifeSciences Holdings Community
NasdaqGS:IART Community
2
Narratives
written by author
0
Comments
on narratives written by author
3
Fair Values set
on narratives written by author
Create a narrative
Integra LifeSciences Holdings
Popular
Undervalued
Overvalued
Community Investing Ideas
Integra LifeSciences Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Advancements In SurgiMend And DuraSorb Will Capitalize On Breast Reconstruction Opportunities
Key Takeaways Global expansion and localization efforts in emerging markets aim to significantly boost international revenue and overall company growth. Facility upgrades and compliance enhancements are expected to optimize production capabilities, supporting revenue growth and potentially improving gross margins.
View narrative
US$15.88
FV
22.1% undervalued
intrinsic discount
4.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
about 11 hours ago
author updated this narrative
Integra LifeSciences Holdings
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
Manufacturing Upgrades And Aging Population Will Create New Opportunities
Key Takeaways Operational improvements and investment in manufacturing will restore product availability, supporting margin growth and expansion into high-demand markets worldwide. Enhanced leadership focus and innovation pipeline accelerate product launches, strengthen global distribution, and position the company for sustained revenue and earnings growth.
View narrative
US$29.78
FV
58.5% undervalued
intrinsic discount
4.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
8 days ago
author updated this narrative
Your Valuation for
IART
IART
Integra LifeSciences Holdings
Your Fair Value
US$
Current Price
US$12.37
79.2% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-29m
2b
2015
2018
2021
2024
2025
2027
2030
Revenue US$2.0b
Earnings US$276.8m
Advanced
Set Fair Value